OCDNCT03511534
Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
A study testing Psychotherapy and Pharmacotherapy in people with OCD, run by Stanford University at 1 site in United States.
Trial summary
The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- OCD
- What is being tested?
- Psychotherapy and Pharmacotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jun 2017to Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to speak and understand English
- Capacity to consent (e.g. as determined by assessing the patient's understanding of the risks, benefits, and procedures of the study)
- Completed an active study protocol at the Rodriguez Lab at Stanford University
Who cannot join
- Children younger than 18
- Active suicidality
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.
Read the detailed description
After completing one of the active clinical studies participants have the option to enroll in this protocol that offers open treatment.
The goal is to compare two forms of current standard treatments, psychotherapy vs pharmacotherapy.
- Conditions
- OCD
- Being tested
- Psychotherapy, Pharmacotherapy
- Keywords
- treatment, psychotherapy, pharmacotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PsychotherapyBehavioural
Evidenced based psychotherapy by a trained psychologist
PharmacotherapyOther
Pharmacotherapy by a psychiatrist
| Study group | Role | What they receive |
|---|---|---|
| Psychotherapy | Active comparator | Participants will receive evidenced based psychotherapy by a trained psychologist Receives: Behavioral: Psychotherapy |
| Pharmacotherapy | Active comparator | Participants will receive pharmacotherapy by a psychiatrist Receives: Other: Pharmacotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.
Measured: Up to 14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2018
- Study start23 Jun 2017
- Primary completionJun 2027 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OCDStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- Participants will choose to enter the psychotherapy or pharmacotherapy arm.
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Carolyn Rodriguez, Stanford University
- Investigators
- Carolyn Rodriguez, MD, PhD, Principal investigator, Assistant Professor, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03511534
- Sponsor's protocol ID
- 41165
- Status last verified
- Aug 2026
- First submitted
- 18 Apr 2018
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
- ClinicalTrials.gov ID
- NCT03511534
- Acronym / sponsor ID
- 41165
- Conditions
- OCD
- Keywords
- treatment, psychotherapy, pharmacotherapy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- 23 Jun 2017 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 30 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.
Detailed description
After completing one of the active clinical studies participants have the option to enroll in this protocol that offers open treatment.
The goal is to compare two forms of current standard treatments, psychotherapy vs pharmacotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will choose to enter the psychotherapy or pharmacotherapy arm.
| Arm | Type | Receives |
|---|---|---|
| Psychotherapy | Active comparator | Behavioral: PsychotherapyParticipants will receive evidenced based psychotherapy by a trained psychologist |
| Pharmacotherapy | Active comparator | Other: PharmacotherapyParticipants will receive pharmacotherapy by a psychiatrist |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Ability to speak and understand English
- Capacity to consent (e.g. as determined by assessing the patient's understanding of the risks, benefits, and procedures of the study)
- Completed an active study protocol at the Rodriguez Lab at Stanford University
Key exclusion criteria (2 listed)
- Children younger than 18
- Active suicidality
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PsychotherapyEvidenced based psychotherapy by a trained psychologist | Behavioural | Psychotherapy |
| PharmacotherapyPharmacotherapy by a psychiatrist | Other | Pharmacotherapy |
Primary outcome
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
Time frame: Up to 14 weeks
Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for OCD
Enrolling by invitation
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
Obsessive - Compulsive Disorder, Family Accommodation
RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Chondral Defect, Osteochondritis Dissecans (OCD)
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carolyn Rodriguez, MD, PhD principal investigator
Assistant Professor, Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychotherapy and Pharmacotherapy in people with OCD, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) (time frame: Up to 14 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.